Haemonetics (NYSE: HAE)
Q1 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-10 | ||||||
REV |
Q4 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | 0.600 | 0.650 | 0.0500 | ||||
REV | 257.820M | 265.002M | 7.182M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Haemonetics (NYSE: HAE) through any online brokerage.
Other companies in Haemonetics’s space includes: RxSight (NASDAQ:RXST), Meridian Bioscience (NASDAQ:VIVO), BioLife Solns (NASDAQ:BLFS), Embecta (NASDAQ:EMBC) and Align Tech (NASDAQ:ALGN).
The latest price target for Haemonetics (NYSE: HAE) was reported by Morgan Stanley on Friday, July 1, 2022. The analyst firm set a price target for 70.00 expecting HAE to rise to within 12 months (a possible 3.81% upside). 10 analyst firms have reported ratings in the last year.
The stock price for Haemonetics (NYSE: HAE) is $67.43 last updated July 1, 2022, 8:00 PM UTC.
There are no upcoming dividends for Haemonetics.
Haemonetics’s Q1 earnings are confirmed for Wednesday, August 10, 2022.
There is no upcoming split for Haemonetics.
Haemonetics is in the Health Care sector and Health Care Equipment & Supplies industry. They are listed on the NYSE.